Cargando…

Financial toxicity in lung cancer

In the United States, lung cancer is the third most common cancer and the overall leading cause of cancer death. Due to advances in immunotherapy and targeted therapy, 5-year survival is increasing. The growing population of patients with lung cancer and cancer survivors highlights the importance of...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulanger, Mary, Mitchell, Carley, Zhong, Jeffrey, Hsu, Melinda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634168/
https://www.ncbi.nlm.nih.gov/pubmed/36338686
http://dx.doi.org/10.3389/fonc.2022.1004102
_version_ 1784824410974191616
author Boulanger, Mary
Mitchell, Carley
Zhong, Jeffrey
Hsu, Melinda
author_facet Boulanger, Mary
Mitchell, Carley
Zhong, Jeffrey
Hsu, Melinda
author_sort Boulanger, Mary
collection PubMed
description In the United States, lung cancer is the third most common cancer and the overall leading cause of cancer death. Due to advances in immunotherapy and targeted therapy, 5-year survival is increasing. The growing population of patients with lung cancer and cancer survivors highlights the importance of comprehensive cancer care, including recognizing and addressing financial toxicity. Financial toxicity is a term used to contextualize the negative effects of the costs of cancer treatment in terms of patient quality of life. The American Society of Clinical Oncology (ASCO) Value Framework places emphasis on high-value care as it evaluates cancer treatments “based on clinical benefit, side effects, and improvements in patient symptoms or quality of life in the context of cost”. Prior studies have shown that risk factors for financial toxicity in patients with lung cancer include lower household income or savings, inability to afford basic necessities, higher than anticipated out of pocket expenses, and taking sick leave. Among lung cancer survivors, patients experience increased unemployment and lower wages compared to the general population underscoring the lasting effects of financial toxicity. Financial toxicity is associated with increased psychosocial distress and decreased quality of life, and bankruptcy is an independent predictor of mortality in patients with cancer. Despite the negative implications of financial toxicity on patients, standardized screening practices and evidence-based interventions are lacking. The “COmphrensive Score for financial Toxicity (COST)” tool has been validated for assessing financial toxicity with correlation with health-related quality of life. Further research is needed to understand the utility of incorporating routine screening for financial toxicity into clinical practice and the efficacy of interventions. Understanding the relationship between financial toxicity and quality of life and survival is critical to providing high-value cancer care and survivorship care.
format Online
Article
Text
id pubmed-9634168
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96341682022-11-05 Financial toxicity in lung cancer Boulanger, Mary Mitchell, Carley Zhong, Jeffrey Hsu, Melinda Front Oncol Oncology In the United States, lung cancer is the third most common cancer and the overall leading cause of cancer death. Due to advances in immunotherapy and targeted therapy, 5-year survival is increasing. The growing population of patients with lung cancer and cancer survivors highlights the importance of comprehensive cancer care, including recognizing and addressing financial toxicity. Financial toxicity is a term used to contextualize the negative effects of the costs of cancer treatment in terms of patient quality of life. The American Society of Clinical Oncology (ASCO) Value Framework places emphasis on high-value care as it evaluates cancer treatments “based on clinical benefit, side effects, and improvements in patient symptoms or quality of life in the context of cost”. Prior studies have shown that risk factors for financial toxicity in patients with lung cancer include lower household income or savings, inability to afford basic necessities, higher than anticipated out of pocket expenses, and taking sick leave. Among lung cancer survivors, patients experience increased unemployment and lower wages compared to the general population underscoring the lasting effects of financial toxicity. Financial toxicity is associated with increased psychosocial distress and decreased quality of life, and bankruptcy is an independent predictor of mortality in patients with cancer. Despite the negative implications of financial toxicity on patients, standardized screening practices and evidence-based interventions are lacking. The “COmphrensive Score for financial Toxicity (COST)” tool has been validated for assessing financial toxicity with correlation with health-related quality of life. Further research is needed to understand the utility of incorporating routine screening for financial toxicity into clinical practice and the efficacy of interventions. Understanding the relationship between financial toxicity and quality of life and survival is critical to providing high-value cancer care and survivorship care. Frontiers Media S.A. 2022-10-21 /pmc/articles/PMC9634168/ /pubmed/36338686 http://dx.doi.org/10.3389/fonc.2022.1004102 Text en Copyright © 2022 Boulanger, Mitchell, Zhong and Hsu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Boulanger, Mary
Mitchell, Carley
Zhong, Jeffrey
Hsu, Melinda
Financial toxicity in lung cancer
title Financial toxicity in lung cancer
title_full Financial toxicity in lung cancer
title_fullStr Financial toxicity in lung cancer
title_full_unstemmed Financial toxicity in lung cancer
title_short Financial toxicity in lung cancer
title_sort financial toxicity in lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634168/
https://www.ncbi.nlm.nih.gov/pubmed/36338686
http://dx.doi.org/10.3389/fonc.2022.1004102
work_keys_str_mv AT boulangermary financialtoxicityinlungcancer
AT mitchellcarley financialtoxicityinlungcancer
AT zhongjeffrey financialtoxicityinlungcancer
AT hsumelinda financialtoxicityinlungcancer